Clinical Trials Actively Recruiting

Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below.

Results 1 - 10 of 59

  • Objective:

    Dual Primary Objectives:

    • To compare progression-free survival (PFS) in frail or selected intermediate fit
      Newly Diagnosed Multiple Myeloma (NDMM) participants treated with VRd-Lite
      induction followed by Lenalidomide maintenance (Arm 1) versus DRd induction
      followed by Lenalidomide maintenance (Arm 2).
    • To compare overall survival (OS) in frail or selected intermediate fit NDMM
      participants treated with VRd-Lite induction followed by lenalidomide maintenance
      (Arm 1) versus DRd induction followed by lenalidomide and daratumumab and
      hyaluronidase-fihj maintenance (Arm 3).

    Secondary Objectives

    • To compare PFS in Arm 1 versus Arm 3
    • To compare OS in Arm 1 versus Arm 2.
    • To compare OS in Arm 2 versus Arm 3, contingent upon significant results from both dual primary endpoints in favor of the respective experimental arms.
    • To compare the overall response rate (ORR) of Arm 1 against the ORR of Arm 2 and Arm 3.
    • To assess the safety of Arm 1 with the safety of Arm 2 and Arm 3.
    • To explore veinous and arterial thrombo-embolism (VTE) incidence in participants receiving lenalidomide during induction across the three study arms.
    • To describe median time to response (CR or better per IMWG criteria, VGPR or better per IMWG criteria, PR or better per IMWG criteria) on the three study arms.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Cole, Craig
    Karmanos Trial ID:
    • S2209
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objective:

    • To compare major organ deterioration progression-free survival between participants randomized to the ASCT and non-ASCT arms of this study.

    Secondary Objectives

    • To compare overall survival (OS) between participants randomized to the ASCT and non-ASCT arms of this study.
    • To compare rates of cardiac and renal organ responses between participants randomized to the ASCT and non-ASCT arms of this study.
    • To compare rates of cardiac and renal organ progression between participants randomized to the ASCT and non-ASCT arms of the study.
    • To compare the frequency and severity of toxicities between participants randomized to the ASCT and non-ASCT arms of this study.
    • To compare minimal residual disease (MRD) negativity rates between participants randomized to the ASCT and non-ACST arms of this study.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Kin, Andrew
    Karmanos Trial ID:
    • S2213
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objectives:

    • To compare the progression-free survival in participants with relapsed/refractory
      large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD)
      or partial remission (PR) on first imaging response by central review (day +30
      PET/CT scan) after commercial CD19 CAR T-cell therapy who are randomized to
      receive each consolidation therapy versus those that receive no consolidation
      therapy (i.e. control). Specifically, to compare the PFS of 1) mosunetuzumab
      consolidation to no consolidation, 2) polatuzumab vedotin consolidation to no
      consolidation, 3) mosunetuzumab + polatuzumab vedotin to no consolidation

    Secondary Objectives:

    • To compare overall survival (OS) in participants randomized to each consolidation
      treatment arm versus control.
    • To compare the complete remission (CR) conversion rate up to one year in
      participants randomized to each consolidation arm versus control.
    • To evaluate the treatment-related adverse events in participants randomized to
      each consolidation arm.
    • To evaluate the association between total metabolic tumor volume (TMTV), SUV
      max, and sum product (SPD) of diameters by PET-CT at first imaging response
      with complete remission conversion up to one year in participants randomized to
      each consolidation arm as well as those randomized to control.
    • To evaluate the overall response rate (ORR), CR rate, PFS, and OS of participants
      randomized to Arm 4 (observation) who have lymphoma progression within 12
      months of CAR T-cell infusion and subsequently ‘cross-over' to receive treatment
      with mosunetuzumab + polatuzumab vedotin.
    • To estimate overall survival for all patients registered to this study.
    • To assess the difference in overall survival between participants who achieved CR
      at first imaging (day +30) versus. those who did not achieve CR at first imaging.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Uberti, Joseph
    Karmanos Trial ID:
    • S2114
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective:
    • To compare overall survival (OS) between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma (MM) patients.
    Secondary Objectives of First Randomization:
    • To compare the best overall response rate (ORR), including partial remission (PR), very good partial remission (VGPR), and complete remission (CR, sCR) in the subset of patients not in PR at randomization to lenalidomide versus lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare progression-free survival (PFS) between the study arms in this patient population.
    • To evaluate MRD-negativity on the two treatment arms at randomization (Registration Step 2), and to compare MRD-negativity rate at 12, 24 (second randomization), 36, and 48 months after first randomization between lenalidomide and lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare toxicities and tolerability of long term therapy between the study arms.
    Objectives of Second Randomization:
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide vs. discontinued lenalidomide from the time of second randomization in this patient population.
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide + daratumumab/rHuPH20 vs. discontinued lenalidomide + daratumumab/rHuPH20 from time of second randomization in this patient population.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Kin, Andrew
    Karmanos Trial ID:
    • S1803
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objective:

    • The primary objective of this study is to assess efficacy of CYP-001 in subjects with HRaGvHD by Overall Response Rate (ORR) at Day 28.

    Secondary Objectives:

    • To assess additional responses and long-term efficacy outcomes
    • To assess Overall Survival (OS)
    • To assess Event-Free survival (EFS)
    • To assess Non-Relapse Mortality (NRM)
    • To assess Failure Free Survival
    • To assess the incidence of Malignancy Relapse/Progression (MR)
    • To measure the incidence of chronic GvHD
    • To assess the cumulative steroid dose until Day 100
    • To evaluate changes in Subject Reported Outcomes
    • To evaluate the safety and tolerability of CYP-001 in subjects with SR-aGvHD
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Uberti, Joseph
    Karmanos Trial ID:
    • 2024-027
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:

    Primary Objective:

    • Part 1: To determine the safety, tolerability, and RP2D of KQB198 as monotherapy and in combination with dasatinib
    • Part 2, Cohort A: To evaluate the efficacy of KQB198 in combination with dasatinib and determine the OBD
    • Part 2, Cohort B: To evaluate the efficacy of KQB198 monotherapy and determine the OBD

    Secondary Objective:

    • Part 1: To evaluate the efficacy of KQB198 as monotherapy and in combination with dasatinib
    • Part 2, Cohorts A and B: To evaluate the efficacy of KQB198 monotherapy and in combination with dasatinib
    • All Parts: To evaluate the safety and tolerability of KQB198 as monotherapy and in combination with dasatinib
    • All Parts: To evaluate the plasma pharmacokinetics (PK) of KQB198 alone or KQB198 and dasatinib when administered in combination
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Yang, Jay
    Karmanos Trial ID:
    • 2024-055
    Age Group:
    • Adult
    Phase:
    • Phase I
  • Objective:
    Primary Objectives:
    • To compare the overall survival (OS) following induction with steroids + TKI + blinatumomab versus induction with steroids + TKI + chemotherapy.

    Secondary Objectives:
    • To compare the rate of MRD negativity for patients treated with chemotherapy vs blinatumomab at the end of first induction (week 15).
    • To evaluate the rate of the MRD negativity by treatment arm for those patients MRD positive after the first induction and administered of second induction.
    • To compare event free survival (EFS) for patients initially randomized for chemotherapy vs blinatumomab. (Events include failure to achieve induction molecular remission by week 15, confirmed molecular relapse after molecular remission or to death in remission).
    • To assess the toxicities of blinatumomab+TKI and steroids + TKI + chemotherapy in this patient population.
    • To assess the toxicities of the chemotherapy regimen in this patient population.
    • To describe the outcome of patients who proceed to allogeneic stem cell transplant after treatment with blinatumomab+TKI only.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Yang, Jay
    Karmanos Trial ID:
    • EA9181
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objective:

    • To evaluate the efficacy of glofitamab in combination with Pola-R-CHP compared with Pola-R-CHP

    Secondary Objectives:

    • To evaluate the efficacy of glofitamab in combination with Pola-R-CHP compared with Pola-R-CHP
    • To evaluate the efficacy of glofitamab in combination with Pola-R-CHP compared with Pola-R-CHP in patients with IPI 3-5
    • To evaluate the efficacy of glofitamab in combination with Pola-R-CHP compared with Pola-R-CHP in
      participants classified to be high-risk based on ctDNA
    • To evaluate the safety of glofitamab in combination with Pola-R-CHP compared with Pola-R-CHP
    • To characterize the glofitamab PK profile in combination with Pola-RCHP
    • To evaluate the immunogenicity of glofitamab in combination with Pola-R-CHP
    • To evaluate the health-related quality of life (HRQoL) of participants treated with glofitamab in
      combination with Pola-R-CHP
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Modi, Dipenkumar
    Karmanos Trial ID:
    • 2024-014
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objective:

    • To compare overall survival in MCL patients in MRD-negative first complete remission (CR) who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone (without auto- HCT).

    Secondary Objectives:

    • To compare progression-free survival in MCL patients in MRDnegative CR who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone.
    • To define the overall survival and progression-free survival at 2 and 5 years of chemosensitive but MRD-positive CR patients who undergo auto-HCT followed by 3 years of maintenance rituximab.
    • To define the overall survival and progression-free survival at 2 and 5 years of chemosensitive but MRD-positive PR patients who undergo auto-HCT followed by 3 years of maintenance rituximab.
    • To define the overall survival and progression-free survival at 2 and 5 years of MRD-negative PR patients who undergo auto-HCT followed by 3 years of maintenance rituximab.
    • To define the overall survival and progression-free survival at 2 and 5 years of MRD-indeterminate patients who undergo auto-HCT followed by 3 years of maintenance rituximab.
    • To describe the rate of complications (serious infection, hospitalization, need for intravenous immune globulin) in MCL patients undergoing maintenance rituximab following auto-HCT.
    • To determine the prognostic impact of MRD status at day 100, in MCL patients who were MRD-positive (including MRD-positive CR and MRD-positive PR) prior to auto-HCT.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Uberti, Joseph
    Karmanos Trial ID:
    • EA4151/BMTCTN1601
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:

    Primary Objectives:

    • To determine the safety and tolerability of each
      protocol-specified ziftomenib combination in
      patients with KMT2A-r or NPM1-m (± co-occurring
      FLT3-m) R/R AML

    Secondary Objectives:

    • To evaluate the antileukemic response for
      ziftomenib combinations in patients with KMT2A-r
      or NPM1-m (± co-occurring FLT3-m) R/R AML
      based on the ELN 2022
    • To evaluate survival and disease control outcomes
      for protocol-specified ziftomenib combinations in
      patients with KMT2A-r or NPM1-m (± co-occurring
      FLT3-m) R/R AML
    • To characterize the PK of ziftomenib and
      metabolites when administered in combination with
      SOC treatments in adults with R/R NPM1-m or
      KMT2A-r AML
    • To evaluate the PK of gilteritinib when
      administered concurrently with ziftomenib in adults
      with R/R NPM1-m (+ co-occurring FLT3-m)
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Balasubramanian, Suresh
    Karmanos Trial ID:
    • 2024-016
    Age Group:
    • Adult
    Phase:
    • Phase I